Opinion|Videos|July 16, 2026
Clinical Evidence: What the Trial Data Tell Pharmacists
Menin inhibitors show promising AML responses—revumenib enables remissions and transplant bridging, while new combinations target KMT2A and NPM1.
Advertisement
Episodes in this series
In this episode, Ali breaks down the pivotal trial data for revumenib and ziftomenib, comparing response rates, transplant outcomes, and patient populations studied. He reveals which efficacy numbers pharmacists should know before their first order review and explains why transplant rate is as clinically meaningful as overall response rate when evaluating therapy success.
Advertisement
Related to this article
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
This quiz was created in collaboration with PTCE™.
Pharmacy professionals can leverage LinkedIn to build a professional brand, expand meaningful connections, share expertise, and create opportunities for career growth.
An Italian pharmacy student offers an inside look at pharmacy education in Italy, from admission and coursework to oral exams and professional training.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
3
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
4
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
5